NCT05060471View on ClinicalTrials.gov

PD-1 Blockade Combined with Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 27, 2021

Primary Completion Date

June 21, 2024

Study Completion Date

November 27, 2024

Conditions
Anal Canal CancerAnal Squamous Cell CarcinomaAnal CancerAnal Canal Cancer Stage IAnal Canal Cancer Stage IIAnal Canal Cancer Stage III
Interventions
DRUG

Toripalimab

Four cycles of neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and two cycles of concurrent toripalimab.

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT05060471 - PD-1 Blockade Combined with Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients | Biotech Hunter | Biotech Hunter